DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Complicated Skin and Skin Structure Infections; Complicated Intra-abdominal Infections

Intervention: Tigecycline (Tygacil) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Clinical Details

Official title: A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Number of Participants With Spontaneous Adverse Events

Detailed description: Three-thousand or 10% of total number of patients given tigecycline will be included in the study

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All patients from the study center who received or will receive at least one dose of

Tygacil according to the approved product indication. Exclusion Criteria:

- Previously discontinued Tygacil therapy due to significant safety concern.

Locations and Contacts

Pfizer Investigational Site, Manila, Philippines
Additional Information

To obtain contact information for a study center near you, click here.

Starting date: April 2007
Last updated: June 9, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017